Objective: Early aortic stenting in chronic type B aortic dissection (TBAD) may lead to long-term benefit, although the optimal treatment strategy is hotly debated. A robust comparison to outcomes seen in medically managed patients is challenging as the rate of antihypertensive medication adherence is unknown. The aims of this study were therefore to identify the rate of antihypertensive medication adherence and predictors of adherence in TBAD.
There has been significant progress in understanding the natural history of type B aortic dissection (TBAD) in recent years. However, the management of TBAD, in particular the management of patients with uncomplicated TBAD, remains hotly debated; it has recently been suggested by a number of authors, supported by trial evidence, that early aortic stenting may be beneficial in the long term. 1, 2 Conservative management of TBAD with medical therapy alone is supported by comprehensive management guidelines. 3, 4 However, late complications, such as dilation in the thoracoabdominal segment, occur, and there is still a concerning 30% cumulative mortality at 5 years in this cohort of patients. 5 Aggressive anti-impulse therapy is the cornerstone of management in the majority of patients with TBAD who are currently managed conservatively. Guidelines recommend goal-directed therapy to achieve a heart rate of <60 beats/min and systolic pressure of 100 to 120 mm Hg, goals that may require a number of pharmacologic agents to achieve. 6, 7 There is increasing evidence now that early surgical intervention may lead to significant long-term benefits, with prophylactic thoracic endovascular aortic repair (TEVAR) promoting aortic remodeling and preventing late complications. 1, 2 However, one criticism of these trials is that unregulated conservative management of patients may be contributing to poor outcomes; one factor may be the compliance of patients with blood pressure-lowering agents. There is considerable evidence that the compliance of patients taking antihypertensives is poor. In the wider UK population, only 37% of hypertensive patients have adequately controlled blood pressure. 8 Meanwhile, 29% of patients with uncontrolled hypertension have either partial or total nonadherence Author conflict of interest: none.
Additional material for this article may be found online at www.jvascsurg.org. to their antihypertensive medication, 9 half of all patients are nonadherent within the first year of starting treatment, and a similar number enjoy a drug holiday on an annual basis. 10 A high level of antihypertensive medication adherence is, understandably, linked to both better blood pressure control and reduced cardiovascular morbidity. 11, 12 While these extremely poor levels of antihypertensive medication adherence are reported in the general population, we do not know whether they are reflective of the level of treatment nonadherence in the late middle-aged male population that forms the majority of the TBAD cohort and who commonly display poor health behaviors. Given this sobering assessment of poor treatment compliance in patients with hypertension, we must challenge whether an evidence-based consensus view on the optimal treatment strategy in TBAD can be made without further knowledge of compliance rates in this population and the impact of this on disease progression and outcomes.
METHODS
Aims. The aim of this study was to assess the rate of self-reported antihypertensive medication adherence in patients with TBAD and furthermore to understand detailed psychological, behavioral, and demographic predictors of adherence behaviors.
Study design. A cross-sectional, mixed methods study was performed at a tertiary center for complex aortic disease. Appropriate ethical approval was obtained through the National Health Service Health Research Authority and a National Health Service Research Ethics Committee (Ref: 16/WS/0018), and informed consent was obtained from all participants. All patients with chronic TBAD taking oral antihypertensive medications who were attending a specialist aortic dissection clinic were prospectively recruited during a 3-month period. Standardized demographic and clinical data were collected, and the study questionnaire was completed at the time of routine clinical review. A validated measure of medication adherence and health behaviors together with an assessment of the patient's disease-specific knowledge was used. In addition, a single-point blood pressure recording was taken at the time of recruitment by a standardized technique. Those patients who chose not to take part or were unable to adequately complete the study questionnaire (eg, because of an inadequate level of English comprehension) were excluded.
Statistical analysis was performed with a computerbased statistical software package (Statistical Package for the Social Sciences [SPSS] 22 for Mac; IBM Corp, Armonk, NY). Descriptive statistics were employed together with a stepwise multiple linear regression analysis to assess demographic, psychological, and behavioral predictors of adherence.
Antihypertensive medication adherence was assessed by the eight-item Morisky Medication Adherence Scale (MMAS-8). Medication adherence may be assessed by either direct (eg, urine metabolite testing or direct observation of the patient) or indirect (eg, self-report or pill counting) methods. 13 All of these methods have their advantages, disadvantages, and limitations; there is no perfect measure of medication adherence. The MMAS-8 is a validated and effective self-report measure of medication adherence across a range of populations of patients, including those with hypertension. [14] [15] [16] [17] [18] Patients answer eight questions related to adherence behaviors, with a composite score of 8/8 indicating high adherence, 6 to <8/8 moderate adherence, and <6/8 low adherence. The composite score may also be used to compare intentional and unintentional nonadherence, with each scored out of 4. Psychological and behavioral predictors of medication adherence were assessed by a questionnaire based on a validated model of health behaviors that aims to predict medication adherence on the basis of value expectancy theory, the value that individuals place on their state and the expectancy that some action will maintain or improve this statedthe Health Belief Model (HBM). [19] [20] [21] [22] The HBM predicts behaviors by examining an individual's beliefs about the disease and treatments across six key domains: perceived susceptibility to the disease and the perceived disease severity; perceived benefit from treatment and any perceived barriers to treatment; cues to action as external triggers for treatment; and self-efficacy as confidence in the correct and effective use of treatment. 22, 23 Furthermore, patients were asked a set of four questions to assess their knowledge about TBAD with a total score marked out of 16; questions were asked on the risk factors, symptoms, and options for management of TBAD using lay terminology and phrasing based on literature commonly distributed to patients. The MMAS-8, HBM questionnaire, and patient knowledge questionnaire are included in the Appendix (online only). Population of patients. There were 61 patients prospectively identified from dissection clinics who were suitable for inclusion in the study. Forty-seven were eventually enrolled; 2 patients were excluded because of inadequate English comprehension, another 11 patients could not be recruited because of a failure to attend their outpatient appointment, and a single patient declined to take part. The demographic and aortic disease characteristics of the study sample are displayed in the 
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RESULTS
The overall level of self-reported antihypertensive medication adherence in patients with TBAD was suboptimal, with a mean MMAS-8 score of 6.65/8. The majority of patients reported suboptimal levels of adherence, with 10 of 47 (21.3%) reporting a low level of adherence, 17 of 47 (36.2%) reporting a moderate level, and only 20 of 47 (42.5%) reporting high levels of antihypertensive medication adherence as seen in Fig 1; consistently high levels of adherence are crucially important for sustained blood pressure control, and those reporting a low or moderate level of adherence may be regarded as being treated suboptimally. In those patients with suboptimal adherence, there was no significant difference between intentional and unintentional nonadherence (3.06/4 vs 2.59/4; P ¼ .059). Of the 47 patients, 4 (8.5%) reported significant perceived side effects from their medications that had an impact on their adherence (postural hypotension, polyuria, and lethargy), but otherwise no specific reasons for nonadherence were alluded to. A stepwise linear regression model was used to assess the correlation between patient variables and adherence; patients who had undergone previous aortic surgery had higher levels of self-reported medication adherence (b ¼ 0.332; P ¼ .03), and those patients who were taking a greater number of medications also reported higher levels of adherence (b ¼ 0.332; P ¼ .026). Given the small cohort and point measures of blood pressure, a true assessment of the correlation between blood pressure and medication adherence is not robust or valid; therefore, as expected, no significant association between adherence and blood pressure was seen.
Our HBM-based questionnaire had acceptable overall internal consistency with a Cronbach a of 0.733, demonstrating it to be a reliable tool for measuring each domain studied. Using the HBM domains to look for psychological and behavioral factors associated with antihypertensive medication adherence in TBAD demonstrated that better memory as a cue to action (b ¼ 0.579; P < .001), fewer medication side effects as a barrier (b ¼ 0.272; P < .014), and higher levels of perceived 
DISCUSSION
This is the first study to evaluate the rate of antihypertensive medication adherence within the TBAD population in addition to identifying some specific psychological and behavioral predictors of adherence. More than half of the patients studied (27/47 [57.5%]) reported suboptimal levels of adherence, and almost one-fifth (10/47 [21.3%]) reported worryingly low levels of adherence, a sobering finding given that the majority of patients with uncomplicated TBAD are currently managed medically, and it is against this treatment regimen that new techniques and treatment strategies are benchmarked.
The self-reported rates of antihypertensive medication adherence reported in this study are similar to those reported in the wider hypertensive population, in which around half of patients are found to be poorly compliant with treatment and frequently drop out of care prematurely or take drug holidays. 10, 24 This may, superficially at least, appear to be of surprise; one would expect that patients who have presented with TBADda potentially life-threatening disorder that is associated with significant long-term morbidity and mortalitydwould understand the benefits of treatment and thus display higher levels of adherence as is seen with other major cardiovascular events. 25 The low levels of adherence in this group of patients may be because of the lack of short-term sequelae from the disease that is seen in many; thus, the impact on adherence is diminished compared with that of other major cardiovascular events that have a far bigger short-term impact and effect on the patient. Only a small number (4/47 [8.5%]) of patients reported side effects of their medication to be a significant barrier to adherence. It is well established that psychosocial factors such as depression, motivation, health beliefs, and knowledge have an important influence on medication adherence. [26] [27] [28] This study has shown that levels of diseasespecific knowledge are low in this TBAD cohort, with an average test score of 8.8 of 16 (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) , fitting with findings in the wider population, in which education of patients about the risks of their disease and the potential benefits from treatment has been shown to minimize negative health behaviors and to improve adherence. 29, 30 A number of patients explicitly stated that "I would like to learn more about how my disease is caused and how my medication helps me," among other illuminating quotes that provide important context in informing patients, developing new interventions to improve adherence, or debating treatment options; more are seen in Fig 2. We found that patients who had previously undergone aortic 25 supporting the assertion that those who remain asymptomatic without significant TBAD sequelae display poorer adherence behaviors and reinforcing the theory that anchoring positive health behaviors to salient events improves compliance with treatment. Our dissection practice builds on this by including specialists in hypertension medicine as part of our integrated care team, facilitating expert education and counseling for the patient, in addition to specialist input decision-making into the medical management of the patient's hypertension to improve treatment strategies and compliance. Aggressive approaches to medical management, such as this intensive "coaching and oversight" of treatment strategies, can improve compliance and outcomes and have been shown to be effective in other cardiovascular diseases. 31, 32 Currently, as a result of one randomized controlled trial, the literature may suggest that there is a survival benefit out to 5 years with TEVAR in uncomplicated TBAD in addition to reduced aorta-specific mortality and disease progression.
2 Furthermore, another trial has shown that TEVAR may promote effective aortic remodeling and false lumen thrombosis at 1 year; without this, around 25% of patients treated conservatively for TBAD will need an intervention within 4 years of diagnosis, 1 and only around 40% remain intervention free at 6 years. 33 Despite this promising evidence, most experts agree that there is no unequivocally clear advantage in early TEVAR, and further randomized prospective studies are needed. 34 Furthermore, there is growing insight into silent conditions that put patients at higher risk of aortic degeneration (resistant hypertension, partial false lumen thrombosis), which means a patient-specific approach must be adopted in considering TEVAR in asymptomatic patients. 35 However, there is still insufficient evidence to truly identify the uncomplicated dissection or to settle on a treatment time frame that supports the use of prophylactic TEVAR while providing enough evidence to facilitate appropriate procedural risk estimation. 36 Whereas TEVAR promotes aortic remodeling and reduces midterm aortic events, 37 it may not be the sensible option for all patients with its very real risk of death, stroke, and paraplegia.
Best medical therapy does demonstrate acceptable early results in terms of mortality and morbidity and remains the mainstay of treatment despite failing to address underlying issues of aortic degeneration and aorta-related adverse events. 38 Poor adherence in patients receiving medical therapy results in poorly controlled blood pressure 9 and subsequent increased aortic morbidity and adverse cardiovascular outcomes. 39 Meanwhile, higher systolic blood pressure readings at night have prognostic significance and are associated with an increased risk of aortic events during follow-up in those with TBAD. 40 Low levels of antihypertensive medication adherence in TBAD may therefore play a part in contributing to the high levels of aortic morbidity and mortality seen in this cohort of patients, particularly in those being managed medically. This is the first study to specifically look at rates of antihypertensive medication adherence in the cohort of TBAD patients. The findings reported are limited by the relatively small study size, the effect of patient selection bias, the treatment strategy, the nuances of local referral and practice, and the heterogeneity of patient demographics and health beliefs that a single-center cohort brings. Furthermore, the results may be influenced by wider health behaviors of the patients; appointment nonattendance and medication nonadherence are closely linked, 41 inevitably affecting recruitment to studies such as this. These results provide a snapshot of adherence behaviors in this cohort, and so there is also clearly an unmet need to further correlate antihypertensive medication adherence with longitudinal blood pressure control and variability and their effects on aortic morphology in the long term. Despite these limitations, the study does, however, shed light on and raise questions about an important and largely ignored aspect of the treatment debate. Further in-depth work on the true level of adherence in the TBAD population and its impact on the natural progression of the disease and aortic morphology is required. TBAD is a distinctive condition that requires an individualized treatment strategy based on a fully evidence-based appraisal of all treatment strategies. Furthermore, it is clear that all patients with TBAD being treated medically would benefit from intensive multidisciplinary follow-up and monitoring to promote positive health behaviors, to ensure maximal treatment adherence, and to identify disease progression at an early stage.
CONCLUSIONS
Medical management of TBAD remains the mainstay of treatment in uncomplicated TBAD despite evidence to support prophylactic TEVAR and the stubbornly poor long-term morbidity and mortality seen in this challenging cohort of patients. The majority of patients with TBAD are poorly adherent to their antihypertensive medications, and this must be robustly addressed and tackled through a multidisciplinary approach. Whereas the relative merits of TEVAR in TBAD are argued, the poor levels of antihypertensive medication adherence in this cohort of patients must be considered an important confounding factor in the treatment debate; one cannot robustly and effectively compare two treatment strategies when half a treatment group may not receive the stated intervention. To develop an evidence-based consensus view on the optimal treatment strategy for TBAD and the impact on aortic morphology and overall morbidity and mortality, we must take into account the direct and indirect effects of both medical therapy and TEVAR. Further work to improve medication adherence and to understand its impact on aortic morphology and disease progression is therefore vitally important to inform the debate and to deliver an evidence-based view on the optimal treatment strategy in the challenging pathologic process of TBAD. Regarding aortic dissection, all those treating the condition understand the serious inherent risks of the problem and the value of medical therapy in reducing progression and complications from this disorder. Martin et al, in the accompanying article, have pointed out the risks for clinicians in simply assuming medication compliance in this high-risk group of patients. In just fewer than 50 patients cared for in an aortic dissection specialty clinic, the authors used a validated, selfreported method to assess medication adherence among the population. The authors noted that less than half the patients (42.5%) reported high levels of medication adherence. A minority of these patients (8.5%) reported perceived side effects from the medication as affecting nonadherence. Importantly, an additional group of 11 patients could not be enrolled in the study because of the patients' failure to attend their outpatient appointments. This overall implies an alarmingly high rate of lack of compliance with therapy and regular medical evaluation.
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This first study to highlight the limitations in adherence to medical therapy in patients with aortic dissection is particularly relevant to current discussions regarding comparisons of medical therapy and endovascular therapy for patients with aortic dissection. The International Registry of Acute Aortic Dissection still recommends medical therapy as the best initial therapy for these patients. In addition, one recent meta-analysis of reports of acute aortic dissection reached a similar conclusion that medical therapy should remain the primary therapy for patients presenting with acute aortic dissection. 1 These assessments are made on the basis of reported outcomes of current medical therapy, which, based on this assessment, is inadequate in the majority of patients. Any therapy comparison for aortic dissection should take into account medication adherence, where the medical therapy is critical to the outcomes of treatment. In the Stenting vs Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial, 2 aggressive medical management was shown to provide significantly improved outcomes compared with interventional therapy for a high-risk condition. In addition, the early improvements in outcomes in these patients were sustained through the trial, prompting an early halt to the randomization. It is critical to ensure that patients treated for aortic dissection are actually getting the medical therapies prescribed. While authors investigate anatomic aortic dissection characteristics that may be indicative of disease progression, it is quite possible there is a higher correlation between lack of adherence to medical therapy and disease progression over time. Before we abandon medical therapy in uncomplicated acute aortic dissection, it is critical to ensure that we are providing good medical care to our patients,
